Can You Test More Treatments While Recruiting Fewer Patients?
Multi-arm clinical trial design has come under increasing focus as rising costs, long timelines and the need to evaluate multiple treatments simultaneously have pushed sponsors and statisticians to seek more efficient approaches to drug development. Rather than running several separate two-arm trials, each with its own control group and recruitment burden, a well-designed multi-arm trial consolidates comparisons into a single unified protocol, saving time, costs, and patients.
In this webinar, Calvin O'Brien, Research Statistician at nQuery, provides an overview of multi-arm clinical trial design with a particular focus on comparison structures, family-wise error rate control, and sample size determination — and how these considerations affect trial design in practice.
Multi-arm clinical trial design offers a more resource-efficient alternative to running several separate two-arm studies. By evaluating multiple treatments simultaneously within a single protocol, sponsors can reduce patient recruitment, save time, and lower costs without sacrificing statistical rigour. However, testing multiple treatments at once introduces the challenge of multiple comparisons, which must be carefully controlled at the design stage.
Key regulatory guidance from both the FDA and EMA reinforces the need for pre-specified multiple testing procedures and strong control of the family-wise error rate, particularly in confirmatory Phase III trials.
Whether it's many-to-one comparisons, all-pairs testing, sample size allocation, or family-wise error rate control, there is a clear interest in re-evaluating every aspect of multi-arm clinical trial design to solve the practical challenges that prevent efficient development programmes.
We begin by examining the fundamentals of multi-arm trials:
This context sets the stage for understanding why multi-arm clinical trial design is not just a methodological option, but an increasingly necessary strategic choice.
Effective multi-arm clinical trial design requires careful pre-specification of several key elements:
With clear regulatory expectations from both the FDA and EMA, sponsors must ensure their multiplicity control strategy is robust, transparent, and pre-specified before confirmatory trials begin.
Accurately determining sample size in a multi-arm setting involves unique considerations compared to standard two-arm trials:
Getting sample size right is critical to ensuring a multi-arm clinical trial is both adequately powered and operationally viable.
The webinar includes hands-on worked examples in nQuery, covering:
These demonstrations show how the theoretical considerations of multi-arm clinical trial design translate directly into practical planning decisions.
About nQuery
nQuery helps make your clinical trials faster, less costly and more successful.
It is an end-to-end platform covering Frequentist, Bayesian, and Adaptive designs with 1000+ sample size procedures.
nQuery Solutions
Sample Size & Power Calculations
Calculate for a Variety of frequentist and Bayesian Design